Medical Sciences Forum (Nov 2022)

Pyridazin-3(2H)-one as New FABP4 Inhibitors Suggested by Molecular Growing Experiments

  • Giuseppe Floresta,
  • Letizia Crocetti,
  • Chiara Zagni,
  • Agostino Cilibrizzi

DOI
https://doi.org/10.3390/ECMC2022-13445
Journal volume & issue
Vol. 14, no. 1
p. 19

Abstract

Read online

The therapeutic potential of fatty acid binding protein 4 (FABP4) is widely acknowledged. Currently, there are numerous clinical studies that indicate how fatty acid binding protein 4 inhibitors could be useful in the treatment of various diseases. To identify new and more potent inhibitors, we utilized a two-step computational approach to design novel structures. Through the use of this approach, we were able to identify a new class of FABP4 inhibitors (FABP4i IC50 2.97 to 23.18 µM) that are capable of inhibiting the activity of FABP4 as low as Arachidonic acid (FABP4i IC50 3.42 ± 0.54 µM). In this study, we present the detailed structural and biological evaluation, and the synthetic procedures of the new pyridazinone-based scaffold FABP4i.

Keywords